Search - tctmd.com

Displaying 1 - 20 of 109

Sort: Relevancy | Date

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

SAVR Bests TAVI in Patients With Highly Calcific Aortic Valves

News Conference News EACTS 2025

SAVR Bests TAVI in Patients With Highly Calcific Aortic Valves

Yael L. Maxwell

October 20, 2025

Solid, Early Surgical Results With Polymer Mitral Valve

News Conference News NY Valves 2025

Solid, Early Surgical Results With Polymer Mitral Valve

July 02, 2025

Promising Early Data With Navitor TAVI Valves

News Conference News NY Valves 2025

Promising Early Data With Navitor TAVI Valves

Yael L. Maxwell

July 02, 2025

Myval Noninferior to Other THVs at 1 Year, but Questions Persist

News Conference News EuroPCR 2025

Myval Noninferior to Other THVs at 1 Year, but Questions Persist

May 21, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

News Conference News ESC 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

September 04, 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

News Conference News NY Valves 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

June 14, 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

News Conference News EuroPCR 2024

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

Michael O'Riordan

May 15, 2024

Myval Matches Contemporary TAVI at 30 Days, but Do More Sizes Matter?

News Conference News EuroPCR 2024

Myval Matches Contemporary TAVI at 30 Days, but Do More Sizes Matter?

May 15, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

News Conference News TCT 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

October 26, 2023

Prior TAVI Patients Needing Non-Aortic Valve Surgery Face Poor Outcomes

News Conference News TVT 2023

Prior TAVI Patients Needing Non-Aortic Valve Surgery Face Poor Outcomes

Michael O'Riordan

June 13, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.